Ultragenyx Pharmaceutical (RARE) EBIT Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) posted EBIT Margin of -35.05% for Q2 2026, up 29.62 percentage points from -64.67% a year earlier and up 89.22 percentage points from the prior quarter.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) EBIT Margin (2016 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBIT Margin at Ultragenyx Pharmaceutical was -73.64%, up 9.17 percentage points year-over-year; for FY2025, it came in at -79.49%, up 16.22 percentage points from FY2024.
- Annual EBIT Margin has increased for three consecutive years, with a five-year change of +42.31 percentage points (FY2020 to FY2025).
- In prior years, Ultragenyx Pharmaceutical's EBIT Margin was -95.71% in FY2024 (+35.39 pp), -131.11% in FY2023 (+47.50 pp), -178.60% in FY2022 (-69.97 pp) and -108.63% in FY2021 (+13.17 pp).
- The Q2 2026 figure stands as the highest quarterly EBIT Margin in data going back to Q2 2016.
- On a year-over-year basis, EBIT Margin increased in six of the last eight quarters, with an average year-over-year change of +19.26 percentage points.
- The strongest year-over-year quarter for EBIT Margin in the past five years was Q3 2023, with a gain of 100.16 percentage points; the weakest was Q3 2022, with a drop of 138.12 percentage points.
- According to Business Quant data, EBIT Margin for the three prior quarters was -124.26% (Q1 2026), -54.65% (Q4 2025) and -106.85% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 28.37% |
| 10 | Ultragenyx Pharmaceutical | 1.62 Bn | -186.47 Mn | 180.00 Mn | -35.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35.05% |
| Mar 31, 2026 | -124.26% |
| Dec 31, 2025 | -54.65% |
| Sep 30, 2025 | -106.85% |
| Jun 30, 2025 | -64.67% |
| Mar 31, 2025 | -102.88% |
| Dec 31, 2024 | -74.28% |
| Sep 30, 2024 | -94.62% |
| Jun 30, 2024 | -79.14% |
| Mar 31, 2024 | -151.93% |
| Dec 31, 2023 | -95.83% |
| Sep 30, 2023 | -147.98% |
| Jun 30, 2023 | -136.61% |
| Mar 31, 2023 | -153.34% |
| Dec 31, 2022 | -140.91% |
| Sep 30, 2022 | -248.14% |
| Jun 30, 2022 | -158.48% |
| Mar 31, 2022 | -170.93% |
| Dec 31, 2021 | -122.99% |
| Sep 30, 2021 | -110.02% |
API Access
Ultragenyx Pharmaceutical EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=RARE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "RARE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=RARE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();